In order to evaluate the influence of PD-L1 and IDO expression on response to immunotherapy and survival, protein expression was assessed in 86 pretreatment melanoma biopsies from patients with metastatic disease before initiation of checkpoint inhibitor therapy. Here, IDO1 is linked to melanoma.